Disease due to mycobacterium simiae and mycobacterium sherrisii in argentina;Enfermedad por mycobacterium simiae y mycobacterium sherrisii en la argentin

Medicina

Volumn 70, Issue 4, 2010, Pages 343-346

  Barrera, Lucia ^a   Palmero, Domingo ^b   Paul, Roxana ^a   Lopez, Beatriz ^a  

^a INEI anLis dr carlos G malbrán ^*

^b Hospital francisco J muñiz

Author keywords

Mycobacterial disease; Mycobacterium sherrisii; Mycobacterium simiae

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; ARGENTINA; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DEATH; DRUG RESPONSE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL HISTORY; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM SHERRISII; MYCOBACTERIUM SIMIAE; SILICOSIS; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ARGENTINA; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; RETROSPECTIVE STUDIES; SILICOSIS; TUBERCULOSIS; YOUNG ADULT;

EID: 79955452666     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. van ingen J, Boeree MJ, Dekhuijzen PN, van soolingen D. Clinical relevance of mycobacterium simiae in pulmonary samples. Eur respir J 2008; 31: 106-109.
2. Maoz C, shitrit D, samara Z, et al. pulmonary myco-bacterium simiae infection: comparison with pulmonary tuberculosis. Eur J clin microbiol infect dis 2008; 27: 945-950.
3. Selvarangan R, Wu W, Nguyen TT, et al. Characterization of a novel group of Mycobacteria and proposal of mycobacterium sherrisii sp. nov. J clin microbiol 2004; 42: 52-59.
4. Gamperli A, Bosshard PP, Sigrist T, et al. pulmonary mycobacterium sherrisii in a human immunodefciency virus type 1-infected patient. J clin microbiol 2005; 43: 4283-4285
5. Lourlergue P, Lamontagne F, Vincent V, Rossier A, Pialoux G. Mycobacterium sherrisii: a new opportunistic agent in hiV infection? aids 2007; 21: 894.
6. Crump JA, van ingen J, Morrisey AB, et al. invasive disease caused by nontuberculous mycobacteria, tanzania. Emerg infect dis 2009; 15: 53-55.
7. Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T.Rapid identifcation of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J clin microbiol 1993; 31: 175-178.
8. CLsi susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard. CLsi (NCCLs) document M24-a CLsi, Wayne, pa, Usa, 2003
9. Griffth DE, Aksamit T, Brown-Elliott BA, et al. An Offcial ats/iDsa statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. am J resp crit care med 2007; 175: 367-416.
10. Valero G, Moreno F, Graybill.activities of clarithromy-cin, ofoxacin, and clarithromycin plus ethambutol against mycobacterium simiae in a murine model of disseminated infection. antimicrob agent chemother 1994; 38: 2676-2677
11. Di Lonardo M, isola NC, ambroggi M, de Bianchi AM, de Kantor IN. Non tuberculous mycobacteriosis in Buenos aires. medicina (buenos aires) 1981; 41: 419-22.